Skip to main content

LRH-1/NR5A2 Y LA FISIOLOGIA DEL ISLOTE PANCREATICO: DESDE LA ORGANOGENESIS Y SUPERVIVENCIA HASTA LA REGENERACION MEDIADA POR INMUNIDAD

BFU2017-83588-P

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D (Excelencia / Generación de Conocimiento)
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD, M.P.

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus

  • Cobo-Vuilleumier, Nadia
  • Lorenzo, Petra Isabel
  • García-Rodríguez, Noelia
  • Gracia Herrera-Gómez, Irene de
  • Fuente-Martín, Esther
  • López-Noriega, Livia
  • Mellado-Gil, José Manuel
  • Romero-Zerbo, Silvana Y.
  • Lachaud, Christian C.
  • Pozo, David
  • Hmadcha, Abdelkrim
  • Toscano, Miguel G.
  • Sánchez-Palazón, Luis
  • Martín-Montalvo, Alejandro
  • Soria Escoms, Bernat
  • Bermúdez-Silva, Francisco Javier
  • Gauthier, Benoit R.
Cobo-Vuilleumier, Nadia et al., Type 1 diabetes mellitus (T1DM) is due to the selective destruction of islet beta cells by immune cells. Current therapies focused on repressing the immune attack or stimulating beta cell regeneration still have limited clinical efficacy. Therefore, it is timely to identify innovative targets to dampen the immune process, while promoting beta cell survival and function. Liver receptor homologue-1 (LRH-1) is a nuclear receptor that represses inflammation in digestive organs, and protects pancreatic islets against apoptosis. Here, we show that BL001, a small LRH-1 agonist, impedes hyperglycemia progression and the immune-dependent inflammation of pancreas in murine models of T1DM, and beta cell apoptosis in islets of type 2 diabetic patients, while increasing beta cell mass and insulin secretion. Thus, we suggest that LRH-1 agonism favors a dialogue between immune and islet cells, which could be druggable to protect against diabetes mellitus., This work was funded by grants from the Juvenile Diabetes Research Foundation (17-2013-372 to B.R.G.), the Consejeria de Salud, Fundacion Publica Andaluza Progreso y Salud, Junta de Andalucia (PI-0727-2010 to B.R.G. and P10CTS6505 to B.S.), Consejeria de Economia, Innovacion y Ciencia (P10.CTS.6359 to B.R.G.), the Ministerio de Economia y Competidividad co-funded by Fondos FEDER (PI10/00871, PI13/00593, and BFU2017-83588-P to B.R.G.; PI14/01015, RD12/0019/0028, and RD16/0011/0034 to B.S.; PI16/00259 to A.H.) and Deutsche Forschungsgemeinschaft (GRK-1789 ´CEMMA´ and DFG SCHI-505/6-1 to R.S.). Special thanks to the families of the DiabetesCero Foundation that graciously supported this work (to B.R.G.). A.M.M. is a recipient of a Miguel Servet grant (CP14/00105) from the Instituto de Salud Carlos III co-funded by Fondos FEDER whereas E.F.M. is a recipient of a Juan de la Cierva Fellowship. I.G.H.G. is supported by a fellowship from Amarna Therapeutics. In some instances, human islets were procured through the European Consortium for Islet Transplantation funded by Juvenile Diabetes Research Foundation (3-RSC-2016-162-I-X)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inadequate control of thyroid hormones sensitizes to hepatocarcinogenesis and unhealthy aging

  • López-Noriega, Livia
  • Capilla-González, Vivian
  • Cobo-Vuilleumier, Nadia
  • Martín-Vázquez, Eugenia
  • Lorenzo, Petra Isabel
  • Martínez-Force, Enrique
  • Soriano-Navarro, Mario
  • García-Fernández, María
  • Romero-Zerbo, Silvana Y.
  • Bermúdez-Silva, Francisco Javier
  • Díaz-Contreras, Irene
  • Sánchez-Cuesta, Ana
  • Santos-Ocaña, Carlos
  • Hmadcha, Abdelkrim
  • Soria Escoms, Bernat
  • Martín, Franz
  • Gauthier, Benoit R.
  • Martín-Montalvo, Alejandro
34 Páginas.-- 7 Figuras.-- 6 Figuras suplementarias.-- 4 Tablas suplementarias, An inverse correlation between thyroid hormone levels and longevity has been reported in several species and reduced thyroid hormone levels have been proposed as a biomarker for healthy aging and metabolic fitness. However, hypothyroidism is a medical condition associated with compromised health and reduced life expectancy. Herein, we show, using wild-type and the Pax8 ablated model of hypothyroidism in mice, that hyperthyroidism and severe hypothyroidism are associated with an overall unhealthy status and shorter lifespan. Mild hypothyroid Pax8 +/- mice were heavier and displayed insulin resistance, hepatic steatosis and increased prevalence of liver cancer yet had normal lifespan. These pathophysiological conditions were precipitated by hepatic mitochondrial dysfunction and oxidative damage accumulation. These findings indicate that individuals carrying mutations on PAX8 may be susceptible to develop liver cancer and/or diabetes and raise concerns regarding the development of interventions aiming to modulate thyroid hormones to promote healthy aging or lifespan in mammals., This work was funded by grants from the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III co-funded by Fondos FEDER and from the nonprofit foundation ‘Fundación Progreso y Salud’ of the Andalusian Regional Ministry of Health (BFU2017-83588-P to B.R.G; CP14/00105, PI18/01590 and PI15/00134 to A.M-M; PI-0272-2017 and CD16/00118 to V.C-G; PI17/01286 to C. S-O and A. S-C)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Transient PAX8 expression in islets during pregnancy correlates with B-cell survival, revealing a novel candidate gene in gestational diabetes mellitus

  • Martín-Montalvo, Alejandro
  • López-Noriega, Livia
  • Jiménez-Moreno, Carmen M.
  • Herranz, Amanda
  • Lorenzo, Petra Isabel
  • Cobo-Vuilleumier, Nadia
  • Tamayo, Alejandra
  • González-Guerrero, Cristian
  • Hofsteede, Jonathan S.W.R.
  • Lebreton, Fanny
  • Bosco, Domenico
  • García Toscano, Miguel
  • Herranz, Lucrecia
  • Anselmo, Joao
  • Moreno, José Carlos
  • Gauthier, Benoit R.
Transient Pax8 expression was reported in mouse islets during gestation, whereas a genome-wide linkage and admixture mapping study highlighted PAX8 as a candidate gene for diabetes mellitus (DM). We sought the significance of PAX8 expression in mouse and human islet biology. PAX8 was induced in gestating mouse islets and in human islets treated with recombinant prolactin. Global gene expression profiling of human and mouse islets overexpressing the corresponding species-specific PAX8 revealed the modulation of distinct genetic pathways that converge on cell survival. Accordingly, apoptosis was reduced in PAX8-overexpressing islets. These findings support that PAX8 could be a candidate gene for the study of gestational DM (GDM). PAX8 was genotyped in patients with GDM and gestational thyroid dysfunction (GTD), a pathology commonly found in patients with mutations on PAX8. A novel missense PAX8 mutation (p.T356M, c.1067C>T) was identified in a female diagnosed with GDM and GTD as well as in her father with type 2 DM but was absent in control patients. The p.T356M variant did not alter protein stability or cellular localization, whereas its transactivation activity was hindered. In parallel, a retrospective clinical analysis uncovered that a pregnant female harboring a second PAX8 mutation (p.P25R, c.74C>G) previously reported to cause congenital hypothyroidism also developed GDM. These data indicate that increased expression of PAX8 affects islet viability and that PAX8 could be considered as a candidate gene for the study of GDM., This work was funded by grants from the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, co-funded by fondos FEDER (CP14/00105 and PI15/00134 to A.M.-M., PI16/00830 to J.C.M., and PI13/00593 and BFU2017-83588-P to B.R.G.). Human islets were procured through the European Consortium for Islet Transplantation funded by JDRF (3- RSC-2016-162-I-X)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pancreatic alpha-cell mass in the early-onset and advanced stage of a mouse model of experimental autoimmune diabetes

  • Bru-Tarí, Eva
  • Cobo-Vuilleumier, Nadia
  • Alonso-Magdalena, Paloma
  • Dos Santos, Reinaldo S.
  • Marroqui, Laura
  • Nadal, Ángel
  • Gauthier, Benoit R.
  • Quesada, Iván
Most studies in type 1 diabetes (T1D) have focused on the loss of the pancreatic beta-cell population. However, despite the involvement of the alpha-cell in the aetiology and complications of T1D, little is known about the regulation of the pancreatic alpha-cell mass in this disease. The need for a better understanding of this process is further emphasized by recent findings suggesting that alpha-cells may constitute a potential reservoir for beta-cell regeneration. In this study, we characterized the pancreatic alpha-cell mass and its regulatory processes in the transgenic RIP-B7.1 mice model of experimental autoimmune diabetes (EAD). Diabetic mice presented insulitis, hyperglycaemia, hypoinsulinemia and hyperglucagonemia along with lower pancreatic insulin content. While alpha-cell mass and pancreatic glucagon content were preserved at the early-onset of EAD, both parameters were reduced in the advanced phase. At both stages, alpha-cell size, proliferation and ductal neogenesis were up-regulated, whereas apoptosis was almost negligible. Interestingly, we found an increase in the proportion of glucagon-containing cells positive for insulin or the beta-cell transcription factor PDX1. Our findings suggest that pancreatic alpha-cell renewal mechanisms are boosted during the natural course of EAD, possibly as an attempt to maintain the alpha-cell population and/or to increase beta-cell regeneration via alpha-cell transdifferentiation., This research was supported by grants from the Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación and Fondo Europeo de Desarrollo Regional (BFU2013-42789; BFU2017-86579-R; BFU2016-77125-R; BFU2017-83588-P), Generalitat Valenciana (PROMETEOII/2015/016) and the Juvenile Diabetes Research Foundation (17-2013-372 to B.R.G.). L.M. holds a Juan de la Cierva fellowship from the Ministerio de Ciencia, Innovación y Universidades (IJCI-2015-24482). CIBERDEM is an initiative of the Instituto de Salud Carlos III.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The atypical cannabinoid Abn-CBD reduces inflammation and protects liver, pancreas, and adipose tissue in a mouse model of prediabetes and non-alcoholic fatty liver disease

  • Romero-Zerbo, Silvana Y.
  • García-Fernández, María
  • Espinosa-Jímenez, Vanesa
  • Pozo-Morales, Macarena
  • Escamilla-Sánchez, Alejandro
  • Sánchez-Salido, Lourdes
  • Lara, Estrella
  • Cobo-Vuilleumier, Nadia
  • Rafacho, Alex
  • Olveira, Gabriel
  • Rojo-Martínez, Gemma
  • Gauthier, Benoit R.
  • González-Mariscal, Isabel
  • Bermúdez-Silva, Francisco Javier
[Background and Aims]: The synthetic atypical cannabinoid Abn-CBD, a cannabidiol (CBD) derivative, has been recently shown to modulate the immune system in different organs, but its impact in obesity-related meta-inflammation remains unstudied. We investigated the effects of Abn-CBD on metabolic and inflammatory parameters utilizing a diet-induced obese (DIO) mouse model of prediabetes and non-alcoholic fatty liver disease (NAFLD)., [Materials and Methods]: Ten-week-old C57Bl/6J mice were fed a high-fat diet for 15 weeks, following a 2-week treatment of daily intraperitoneal injections with Abn-CBD or vehicle. At week 15 mice were obese, prediabetic and developed NAFLD. Body weight and glucose homeostasis were monitored. Mice were euthanized and blood, liver, adipose tissue and pancreas were collected and processed for metabolic and inflammatory analysis., [Results]: Body weight and triglycerides profiles in blood and liver were comparable between vehicle- and Abn-CBD-treated DIO mice. However, treatment with Abn-CBD reduced hyperinsulinemia and markers of systemic low-grade inflammation in plasma and fat, also promoting white adipose tissue browning. Pancreatic islets from Abn-CBD-treated mice showed lower apoptosis, inflammation and oxidative stress than vehicle-treated DIO mice, and beta cell proliferation was induced. Furthermore, Abn-CBD lowered hepatic fibrosis, inflammation and macrophage infiltration in the liver when compared to vehicle-treated DIO mice. Importantly, the balance between hepatocyte proliferation and apoptosis was improved in Abn-CBD-treated compared to vehicle-treated DIO mice., [Conclusions]: These results suggest that Abn-CBD exerts beneficial immunomodulatory actions in the liver, pancreas and adipose tissue of DIO prediabetic mice with NAFLD, thus protecting tissues. Therefore, Abn-CBD and related compounds could represent novel pharmacological strategies for managing obesity-related metabolic disorders., This work was supported by Consejería de Salud de la Junta de Andalucía Andalucía se mueve con Europa (PI-0574-2012 to SR-Z) and Instituto de Salud Carlos III (ISCIII), Ministerio de Sanidad, Gobierno de España Una manera de hacer Europa (13/00309 and 17/01004 to FB-S, co-funded by FEDER, EU). SR-Z was recipient of a postdoctoral fellowship from Consejeria de Salud de la Junta de Andalucia (RH-0070-2013). AR received a short-term stay fellowship from Banco Santander (Programa Bolsas Iberoamericanas Jovens Professores e Pesquisadores) and was funded by a CNPq research grant (Grant No. 306359/2017-0). IG-M was funded by the European Commission Research & Innovation, Horizon2020 program, call H2020-MSCA-IF-2016 (GA: 748749). FB-S belongs to the regional Nicolás Monardes research program of the Consejería de Salud (C-0070-2012 and RC0005-2016; Junta de Andalucía, Spain). BG was supported by the Ministerio de Economia y Competitividad co-funded by FEDER (PI10/00871, PI13/00593 and BFU2017-83588-P). CIBERDEM is an initiative of the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Therapeutic potential of mesenchymal stem cells for cancer therapy

  • Hmadcha, Abdelkrim
  • Martín-Montalvo, Alejandro
  • Gauthier, Benoit R.
  • Soria Escoms, Bernat
  • Capilla-González, Vivian
Mesenchymal stem cells (MSCs) are among the most frequently used cell type for regenerative medicine. A large number of studies have shown the beneficial effects of MSC-based therapies to treat different pathologies, including neurological disorders, cardiac ischemia, diabetes, and bone and cartilage diseases. However, the therapeutic potential of MSCs in cancer is still controversial. While some studies indicate that MSCs may contribute to cancer pathogenesis, emerging data reported the suppressive effects of MSCs on cancer cells. Because of this reality, a sustained effort to understand when MSCs promote or suppress tumor development is needed before planning a MSC-based therapy for cancer. Herein, we provide an overview on the therapeutic application of MSCs for regenerative medicine and the processes that orchestrates tissue repair, with a special emphasis placed on cancer, including central nervous system tumors. Furthermore, we will discuss the current evidence regarding the double-edged sword of MSCs in oncological treatment and the latest advances in MSC-based anti-cancer agent delivery systems., The authors received financial support from the Andalusian Regional Ministry of Health (PI-0272-2017), the Institute of Health Carlos III, and the Spanish Ministry of Science, Innovation and University, co-funded by Fondos FEDER (CD16/00118, CP19/00046, PI16/00259, BFU2017-83588-P, CP14/00105, PI18/01590, PI17/02104, PIC18/0010, and IC19/0052), the JDRF (2-SRA-2019-837-S-B), and the crowdfunding platform PRECIPITA of the Spanish Foundation for Science and Technology (2018-000237)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The T1D-associated lncRNA Lnc13 modulates human pancreatic β cell inflammation by allele-specific stabilization of STAT1 mRNA

  • Gonzalez-Moro, Itziar
  • Olazagoitia-Garmendia, Ane
  • Colli, Maikel L.
  • Cobo-Vuilleumier, Nadia
  • Postler, Thomas S.
  • Marselli, Lorella
  • Marchetti, Piero
  • Ghosh, Sankar
  • Gauthier, Benoit R.
  • Eizirik, Decio L.
  • Castellanos-Rubio, Ainara
  • Santin, Izortze
The vast majority of type 1 diabetes (T1D) genetic association signals lie in noncoding regions of the human genome. Many have been predicted to affect the expression and secondary structure of long noncoding RNAs (lncRNAs), but the contribution of these lncRNAs to the pathogenesis of T1D remains to be clarified. Here, we performed a complete functional characterization of a lncRNA that harbors a single nucleotide polymorphism (SNP) associated with T1D, namely, Lnc13. Human pancreatic islets harboring the T1D-associated SNP risk genotype in Lnc13 (rs917997*CC) showed higher STAT1 expression than islets harboring the heterozygous genotype (rs917997*CT). Up-regulation of Lnc13 in pancreatic β-cells increased activation of the proinflammatory STAT1 pathway, which correlated with increased production of chemokines in an allele-specific manner. In a mirror image, Lnc13 gene disruption in β-cells partially counteracts polyinosinic-polycytidylic acid (PIC)-induced STAT1 and proinflammatory chemokine expression. Furthermore, we observed that PIC, a viral mimetic, induces Lnc13 translocation from the nucleus to the cytoplasm promoting the interaction of STAT1 mRNA with (poly[rC] binding protein 2) (PCBP2). Interestingly, Lnc13-PCBP2 interaction regulates the stability of the STAT1 mRNA, sustaining inflammation in β-cells in an allele-specific manner. Our results show that the T1D-associated Lnc13 may contribute to the pathogenesis of T1D by increasing pancreatic β-cell inflammation. These findings provide information on the molecular mechanisms by which disease-associated SNPs in lncRNAs influence disease pathogenesis and open the door to the development of diagnostic and therapeutic approaches based on lncRNA targeting., This work was supported by a Research Project Grant from the Basque Department of Health (2015111068) and a Research Grant from Fundación de la Sociedad Española de Diabetes (FSED) to I.S. I.G.-M. and A.O.-G. were supported by Predoctoral Fellowship Grants from the UPV/EHU (Universidad del Pais Vasco/Euskal Herriko Unibertsitatea) and the Basque Department of Education, respectively. A.C.-R. was funded by a Grant from the Spanish Ministry of Science, Innovation and Universities (PGC2018-097573-A-I00). D.L.E. received support from the Fonds National de la Recherche 420 Scientifique (FNRS), Welbio Grant CR-2015A-06. B.R.G. was funded by the Spanish Ministry of Science, Innovation and Universities; the European Fund for Regional Development (FEDER) (Grant BFU2017-83588-P); and the Juvenile Diabetes Research Foundation (Grants 17-2013-372 and 2-SRA-2019-837-S-B)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Time for a paradigm shift in treating type 1 diabetes mellitus: coupling inflammation to islet regeneration

  • Cobo-Vuilleumier, Nadia
  • Gauthier, Benoit R.
Type 1 diabetes mellitus (T1DM) is an autoimmune disease that targets the destruction of islet beta-cells resulting in insulin deficiency, hyperglycemia and death if untreated. Despite advances in medical devices and longer-acting insulin, there is still no robust therapy to substitute and protect beta-cells that are lost in T1DM. Attempts to refrain from the autoimmune attack have failed to achieve glycemic control in patients highlighting the necessity for a paradigm shift in T1DM treatment. Paradoxically, beta-cells are present in T1DM patients indicating a disturbed equilibrium between the immune attack and beta-cell regeneration reminiscent of unresolved wound healing that under normal circumstances progression towards an anti-inflammatory milieu promotes regeneration. Thus, the ultimate T1DM therapy should concomitantly restore immune self-tolerance and replenish the beta-cell mass similar to wound healing. Recently the agonistic activation of the nuclear receptor LRH-1/NR5A2 was shown to induce immune self-tolerance, increase beta-cell survival and promote regeneration through a mechanism of alpha-to-beta cell phenotypic switch. This trans-regeneration process appears to be facilitated by a pancreatic anti-inflammatory environment induced by LRH-1/NR5A2 activation. Herein, we review the literature on the role of LRH1/NR5A2 in immunity and islet physiology and propose that a cross-talk between these cellular compartments is mandatory to achieve therapeutic benefits., The research of B.R.G is/was supported by the Juvenile Diabetes Research Foundation (17-2013-372 and 2-SRA-2019-837-S-B), the DiabetesCero Foundation, Vencer el Cancer, ALUSVI, the Consejeria de Salud, Fundacion Publica Andaluza Progreso y Salud, Junta de Andalucia (PI-0727-2010), Consejeria de Economia, Innovacion y Ciencia (P10.CTS.6359) and the Ministerio de Economia y Competidividad co-funded by Fondos FEDER (PI10/00871, PI13/00593 and BFU2017-83588-P)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Thyroid hormones in diabetes, cancer, and aging

  • Gauthier, Benoit R.
  • Sola-García, Alejandro
  • Cáliz-Molina, María Ángeles
  • Lorenzo, Petra Isabel
  • Cobo-Vuilleumier, Nadia
  • Capilla-González, Vivian
  • Martín-Montalvo, Alejandro
Thyroid function is central in the control of physiological and pathophysiological processes. Studies in animal models and human research have determined that thyroid hormones modulate cellular processes relevant for aging and for the majority of age-related diseases. While several studies have associated mild reductions on thyroid hormone function with exceptional longevity in animals and humans, alterations in thyroid hormones are serious medical conditions associated with unhealthy aging and premature death. Moreover, both hyperthyroidism and hypothyroidism have been associated with the development of certain types of diabetes and cancers, indicating a great complexity of the molecular mechanisms controlled by thyroid hormones. In this review, we describe the latest findings in thyroid hormone research in the field of aging, diabetes, and cancer, with a special focus on hepatocellular carcinomas. While aging studies indicate that the direct modulation of thyroid hormones is not a viable strategy to promote healthy aging or longevity and the development of thyromimetics is challenging due to inefficacy and potential toxicity, we argue that interventions based on the use of modulators of thyroid hormone function might provide therapeutic benefit in certain types of diabetes and cancers., The authors receive financial support from the Institute of Health Carlos III and the Spanish Ministry of Science, Innovation and University, co‐funded by Fondos FEDER/Fondo social Europeo (PI18/01590 and CPII19/00023 to A.M‐M; CP19/00046 to V.C‐G, FI19/00162 to ASG, and BFU2017‐83588‐P to BRG), the Andalusian Regional Ministry of Health (C2‐0024‐2019 to A.M‐M and PI‐0272‐2017 to V.C‐G).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Obesity-Induced Astrogliosis Is Regulated by the Diabesity Factor HMG20A

  • Mellado-Gil, José Manuel
  • Fuente-Martín, Esther
  • Lorenzo, Petra Isabel
  • Cobo-Vuilleumier, Nadia
  • Guerrero-Martínez, José A.
  • Romero-Zerbo, Silvana Y.
  • Franco, Jaime M.
  • Pérez-Cabello, Jesús Ángel
  • Álvarez-Dolado, Manuel
  • Pozo, David
  • Bermúdez-Silva, Francisco Javier
  • Reyes, José C.
  • Gauthier, Benoit R.
Resumen del trabajo presentado en el American Diabetes Association Meeting (2020), celebrado online del 12 al 16 de junio de 2020, It is well established that systemic glucose homeostasis is imparted by an intricate cross-talk among several organs including the central nervous system (CNS) and pancreatic islets. In analogy to islet beta cells, hypothalamic astrocytes are glucose sensors that facilitate the CNS response to changing metabolic environment. Therefore, astrocytes and beta cells may share a common genetic signature implicated in coupling glucose metabolism to cellular output. We recently demonstrated that the diabesity factor HMG20A is essential for beta-cell functional maturity and adaptation to physiological stress (obesity, type 2 diabetes and pregnancy). As this chromatin remodelling factor also dictates CNS development, we sought to determine whether HMG20A is expressed in astrocytes and whether it potentiates astrocyte function in response to environmental cues. We found that HMG20A is expressed in hypothalamic astrocytes and is upregulated in diet-induced obesity and glucose-intolerant mice, correlating with increased transcript levels of GFAP and IL-1β, indicative of reactive astrocytes (astrogliosis). High glucose, but not lipids, transiently decreased HMG20A expression in isolated mouse primary astrocytes. HMG20A silencing in astrocytes resulted in repression of pro-inflammatory as well as lipid and glucose metabolism genes. These pathways are up-regulated in activated astrocytes (astrogliosis) to resolve stress conditions. As such astrocyte depleted of HMG20A were more susceptible to cell death. Furthermore, motor neuron viability in astrocyte conditioned media was significantly hindered after HMG20A depletion in astrocytes. We posit that HMG20A is involved in the astrocyte polarization state. Under physiological pressure such as obesity, HMG20A expression may be transiently decreased by high glucose but long-term it is increased to induce astrogliosis in an attempt to preserve the neuronal network and glucose homeostasis., ISCIII (PI13/00593 to B.R.G.), (PI13/00309 to F.J.B-S.); Ministerio de Economia y Competidividad/Fondos FEDER (PI10/00871, PI13/00593, BFU2017-83588-P to B.R.G.); BFU2017-85420-R (to J.C.R.); (JCI-2012-12491, IJCI-2015-26238 to E.F-M.); Consejería de Salud Junta de Andalucía (PI-0006-2016 to E.F-M.), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Harnessing the endogenous plasticity of pancreatic islets: A feasible regenerative medicine therapy for diabetes?

  • Lorenzo, Petra Isabel
  • Cobo-Vuilleumier, Nadia
  • Martín-Vázquez, Eugenia
  • López-Noriega, Livia
  • Gauthier, Benoit R.
Diabetes is a chronic metabolic disease caused by an absolute or relative deficiency in functional pancreatic β‐cells that leads to defective control of blood glucose. Current treatments for diabetes, despite their great beneficial effects on clinical symptoms, are not curative treatments, leading to a chronic dependence on insulin throughout life that does not prevent the secondary complications associated with diabetes. The overwhelming increase in DM incidence has led to a search for novel antidiabetic therapies aiming at the regeneration of the lost functional β‐cells to allow the re‐establishment of the endogenous glucose homeostasis. Here we review several aspects that must be considered for the development of novel and successful regenerative therapies for diabetes: first, the need to maintain the heterogeneity of islet β‐cells with several subpopulations of β‐cells characterized by different transcriptomic profiles correlating with differences in functionality and in resistance/behavior under stress conditions; second, the existence of an intrinsic islet plasticity that allows stimulus‐mediated transcriptome alterations that trigger the transdifferentiation of islet non‐β‐cells into β‐cells; and finally, the possibility of using agents that promote a fully functional/mature β‐cell phenotype to reduce and reverse the process of dedifferentiation of β‐cells during diabetes., Authors were/are funded by grants from Consejería de Salud, Fundación Pública Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010, December 2010 to B.R.G., PI-0085-2013, December 2013 to P.I.L., and PI-0001-2020, December 2020 to B.R.G. and P.I.L.); Consejería de Economía, Innovación y Ciencia, Junta de Andalucía (P10-CTS-6359 to B.R.G.); Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, cofunded by Fondos FEDER (PI10/00871, January 2011 and PI13/00593, January 2014 to B.R.G.); Ministerio de Economía y Competitividad, Plan Nacional (BFU2017-83588-P, January 2018 to B.R.G. and PRE2018-084907, January 2018 to E.M.-V.); Juvenile Diabetes Research Foundation JDRF (17-2013-372, August 2013 and 2-SRA-2019-837-S-B, August 2019 to B.R.G:); and Fundacion Vencer el Cancer (to B.R.G.). Special thanks to ALUSVI (Asociación Lucha y Sonríe por la Vida, Pilas), a local Andalusian association, and the Fundacion DiabetesCero for their unconditional financial support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Nuclear envelope integrity in health and disease: Consequences on genome instability and inflammation

  • Gauthier, Benoit R.
  • Comaills, Valentine
The dynamic nature of the nuclear envelope (NE) is often underestimated. The NE protects, regulates, and organizes the eukaryote genome and adapts to epigenetic changes and to its environment. The NE morphology is characterized by a wide range of diversity and abnormality such as invagination and blebbing, and it is a diagnostic factor for pathologies such as cancer. Recently, the micronuclei, a small nucleus that contains a full chromosome or a fragment thereof, has gained much attention. The NE of micronuclei is prone to collapse, leading to DNA release into the cytoplasm with consequences ranging from the activation of the cGAS/STING pathway, an innate immune response, to the creation of chromosomal instability. The discovery of those mechanisms has revolutionized the understanding of some inflammation-related diseases and the origin of complex chromosomal rearrangements, as observed during the initiation of tumorigenesis. Herein, we will highlight the complexity of the NE biology and discuss the clinical symptoms observed in NE-related diseases. The interplay between innate immunity, genomic instability, and nuclear envelope leakage could be a major focus in future years to explain a wide range of diseases and could lead to new classes of therapeutics., Authors were/are funded by grants from the Spanish association against the Cancer AECC (Aecc investigator to V.C. INVES20033COMA) and from the Fundación Vencer el Cáncer (to B.R.G. and V.C). B.R.G. was/is funded by grants from Consejería de Salud, Fundación Pública AndaluzaProgreso y Salud, Junta de Andalucía (PI-0727-2010, December 2010 to B.R.G. and PI-0001- 2020, December 2020 to B.R.G.); Consejería de Economía, Innovación y Ciencia, Junta de Andalucía (P10-CTS-6359 to B.R.G.); Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, cofunded by Fondos FEDER (PI10/00871, January 2011and PI13/00593, January 2014 to B.R.G.); Ministerio de Economía y Competitividad, Plan Nacional(BFU2017-83588-P, January 2018 to B.R.G.); JuvenileDiabetes Research Foundation JDRF (17-2013-372, August 2013 and 2-SRA-2019-837-S-B, August 2019 to B.R.G.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The metabesity factor HMG20A potentiates astrocyte survival and reactive astrogliosis preserving neuronal integrity

  • Lorenzo, Petra Isabel
  • Martín-Vázquez, Eugenia
  • López-Noriega, Livia
  • Fuente-Martín, Esther
  • Mellado-Gil, José Manuel
  • Franco, Jaime M.
  • Cobo-Vuilleumier, Nadia
  • Guerrero-Martínez, José A.
  • Romero-Zerbo, Silvana Y.
  • Pérez-Cabello, Jesús Ángel
  • Rivero, Sabrina
  • Campos-Caro, Antonio
  • Lachaud, Christian C.
  • Crespo Barreda, Alejandra
  • Aguilar-Diosdado, Manuel
  • García Fuentes, Eduardo
  • Martín-Montalvo, Alejandro
  • Álvarez-Dolado, Manuel
  • Martín, Franz
  • Rojo-Martínez, Gemma
  • Pozo, David
  • Bermúdez-Silva, Francisco Javier
  • Comaills, Valentine
  • Reyes, José C.
  • Gauthier, Benoit R.
Rationale: We recently demonstrated that the Metabesity factor HMG20A regulates islet beta-cell functional maturity and adaptation to physiological stress such as pregnancy and pre-diabetes. HMG20A also dictates central nervous system (CNS) development via inhibition of the LSD1-CoREST complex but its expression pattern and function in adult brain remains unknown. Herein we sought to determine whether HMG20A is expressed in the adult CNS, specifically in hypothalamic astrocytes that are key in glucose homeostasis and whether similar to islets, HMG20A potentiates astrocyte function in response to environmental cues. Methods: HMG20A expression profile was assessed by quantitative PCR (QT-PCR), Western blotting and/or immunofluorescence in: 1) the hypothalamus of mice exposed or not to either a high-fat diet or a high-fat high-sucrose regimen, 2) human blood leukocytes and adipose tissue obtained from healthy or diabetic individuals and 3) primary mouse hypothalamic astrocytes exposed to either high glucose or palmitate. RNA-seq and cell metabolic parameters were performed on astrocytes treated or not with a siHMG20A. Astrocyte-mediated neuronal survival was evaluated using conditioned media from siHMG20A-Treated astrocytes. The impact of ORY100. An Inhibitor Of The LSD1-CoREST Complex, On Hmg20a Expression, Reactive Astrogliosis And Glucose Metabolism Was Evaluated In Vitro And In Vivo In High-Fat High-Sucrose Fed Mice. Results: We Show That Hmg20a Is Predominantly Expressed In Hypothalamic Astrocytes, The Main Nutrient-Sensing Cell Type Of The Brain. Hmg20a Expression Was Upregulated In Diet-Induced Obesity And Glucose Intolerant Mice, Correlating With Increased Transcript Levels Of Gfap And Il1b Indicative Of Inflammation And Reactive Astrogliosis. Hmg20a Transcript Levels Were Also Increased In Adipose Tissue Of Obese Non-Diabetic Individuals As Compared To Obese Diabetic Patients. Hmg20a Silencing In Astrocytes Resulted In Repression Of Inflammatory, Cholesterol Biogenesis And Epithelial-To-Mesenchymal Transition Pathways Which Are Hallmarks Of Reactive Astrogliosis. Accordingly, Hmg20a Depleted Astrocytes Exhibited Reduced Mitochondrial Bioenergetics And Increased Susceptibility To Apoptosis. Neuron Viability Was Also Hindered In HMG20A-Depleted Astrocyte-Derived Conditioned Media. Ory1001 Treatment Rescued Expression Of Reactive Astrogliosis-Linked Genes In Hmg20a Ablated Astrocytes While Enhancing Cell Surface Area, Gfap Intensity And Stat3 Expression In Healthy Astrocytes, Mimicking The Effect Of Hmg20a. Furthermore, Ory1001 Treatment Protected Against Obesity-Associated Glucose Intolerance In Mice Correlating With A Regression Of Hypothalamic Hmg20a Expression, Indicative Of Reactive Astrogliosis Attenuation With Improved Health Status. Conclusion: Hmg20a Coordinates The Astrocyte Polarization State. Under Physiological Pressure Such As Obesity And Insulin Resistance That Induces Low Grade Inflammation, Hmg20a Expression Is Increased To Induce Reactive Astrogliosis In An Attempt To Preserve The Neuronal Network And Re-Establish Glucose Homeostasis. Nonetheless, A Chronic Metabesity State Or Functional Mutations Will Result In Lower Levels Of Hmg20a, Failure To Promote Reactive Astrogliosis And Increase Susceptibility Of Neurons To Stress-Induced Apoptosis. Such Effects Could Be Reversed By Ory1001 Treatment Both In Vitro And In Vivo, Paving The Way For A New Therapeutic Approach For Type 2 Diabetes Mellitus., The authors are supported by grants from the Consejería de Salud, Fundación Pública Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010 and PI-0001-2020 to B.R.G.; PI-0085-2013 to P.I.L.; PI-0006-2016 to E.F.M.; PI-0574-2012 to S.Y.R.Z; PI-0247-2016 to F.J.B.S.), the Consejería de Economía, Innovación y Ciencia (P10.CTS.6359 to B.R.G.; CTS.8081 to E.G.F.), the Ministerio de Economía y Competitividad co-funded by Fondos FEDER (PI10/00871, PI13/00593 and BFU2017-83588-P to B.R.G.; PRE2018-084907 to M.E.M.V.G.; PI13/00309; PI17/01004 to F.J.B.S.; BFU2014-5343-P to J.C.R.; and AGL2017-86927-R to F.M.), Vencer el Cancer (B.R.G), DiabetesCero (B.R.G.) and the Juvenile Diabetes Research Foundation (17-2013-372 and 2-SRA-2019-837-S-B to B.R.G.). E.F.M. was a recipient of a Juan de la Cierva Incorporación Fellowship from the Ministerio de Economía y Competitividad (IJCI-2015-26238). S.Y.R.Z is a recipient of a postdoctoral fellowship from Consejería de Salud, Junta de Andalucía (RH-0070-2013). L.L.N. is supported by a Consejeria de Economia, Conocimiento, Empresas y Universidad postdoctoral fellowship (DOC_00652). F.J.B.S. and E.G.F. are recipients of "Nicolás Monardes" research contracts from Consejería de Salud Junta de Andalucía, (C-0070-2012 and C-0031-2016). A.M.M. is supported by CPII19/00023 and PI18/01590 from the Instituto de Salud Carlos III co-funded by Fondos FEDER. CIBERDEM is an initiative of the Instituto de Salud Carlos III. V.C. is supported by a AECC investigator award.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Physical forces and transient nuclear envelope rupture during metastasis: The key for success?

  • Gauthier, Benoit R.
  • Lorenzo, Petra Isabel
  • Comaills, Valentine
During metastasis, invading tumor cells and circulating tumor cells (CTC) face multiple mechanical challenges during migration through narrow pores and cell squeezing. However, little is known on the importance and consequences of mechanical stress for tumor progression and success in invading a new organ. Recently, several studies have shown that cell constriction can lead to nuclear envelope rupture (NER) during interphase. This loss of proper nuclear compartmentalization has a profound effect on the genome, being a key driver for the genome evolution needed for tumor progression. More than just being a source of genomic alterations, the transient nuclear envelope collapse can also support metastatic growth by several mechanisms involving the innate immune response cGAS/STING pathway. In this review we will describe the importance of the underestimated role of cellular squeezing in the progression of tumorigenesis. We will describe the complexity and difficulty for tumor cells to reach the metastatic site, detail the genomic aberration diversity due to NER, and highlight the importance of the activation of the innate immune pathway on cell survival. Cellular adaptation and nuclear deformation can be the key to the metastasis success in many unsuspected aspects., V.C. is funded by the Spanish association against the Cancer AECC investigator grant (INVES20033COMA). V.C. and B.R.G. are funded from the Fundación Vencer el Cancer. B.R.G. and P.I.L. were/are funded by grants from Consejería de Salud, Fundación Pública Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010, December 2010 to B.R.G., PI-0085-2013, December 2013 to P.I.L., and P20_00315, December 2020 to B.R.G. and P.I.L.); Consejería de Economía, Innovación y Ciencia, Junta de Andalucía (P10-CTS-6359 to B.R.G.); Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, cofunded by Fondos FEDER (PI10/00871, January 2011 and PI13/00593, January 2014 to B.R.G.); Ministerio de Economía y Competitividad, Plan Nacional (BFU2017-83588-P, January 2018 to B.R.G.); Juvenile Diabetes Research Foundation JDRF (17-2013-372, August 2013 and 2-SRA-2019-837-S-B, August 2019 to B.R.G.); Special thanks to ALUSVI (Asociación Lucha y Sonríe por la Vida, Pilas), a local Andalusian association, and the Fundacion DiabetesCERO for their unconditional financial support
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Abnormal cannabidiol ameliorates inflammation preserving pancreatic beta cells in mouse models of experimental type 1 diabetes and beta cell damage

  • González-Mariscal, Isabel
  • Pozo-Morales, Macarena
  • Romero-Zerbo, Silvana Y.
  • Espinosa-Jímenez, Vanesa
  • Escamilla-Sánchez, Alejandro
  • Sánchez-Salido, Lourdes
  • Cobo-Vuilleumier, Nadia
  • Gauthier, Benoit R.
  • Bermúdez-Silva, Francisco Javier
The atypical cannabinoid Abn-CBD improves the inflammatory status in preclinical models of several pathologies, including autoimmune diseases. However, its potential for modulating inflammation in autoimmune type 1 diabetes (T1D) is unknown. Herein we investigate whether Abn-CBD can modulate the inflammatory response during T1D onset using a mouse model of T1D (non-obese diabetic- (NOD)-mice) and of beta cell damage (streptozotocin (STZ)-injected mice). Six-week-old female NOD mice were treated with Abn-CBD (0.1–1 mg/kg) or vehicle during 12 weeks and then euthanized. Eight-to-ten-week-old male C57Bl6/J mice were pre-treated with Abn-CBD (1 mg/kg of body weight) or vehicle for 1 week, following STZ challenge, and euthanized 1 week later. Blood, pancreas, pancreatic lymph nodes (PLNs) and T cells were collected and processed for analysis. Glycemia was also monitored. In NOD mice, treatment with Abn-CBD significantly reduced the severity of insulitis and reduced the pro-inflammatory profile of CD4 T cells compared to vehicle. Concomitantly, Abn-CBD significantly reduced islet cell apoptosis and improved glucose tolerance. In STZ-injected mice, Abn-CBD decreased circulating proinflammatory cytokines and ameliorated islet inflammation reducing intra-islet phospho-NF-κB and TXNIP. Abn-CBD significantly reduced 2 folds intra-islet CD8 T cells and reduced Th1/non-Th1 ratio in PLNs of STZ-injected mice. Islet cell apoptosis and intra-islet fibrosis were also significantly reduced in Abn-CBD pre-treated mice compared to vehicle. Altogether, Abn-CBD reduces circulating and intra-islet inflammation, preserving islets, thus delaying the progression of insulitis. Hence, Abn-CBD and related compounds emerge as new candidates to develop pharmacological strategies to treat the early stages of T1D., H2020-MSCA-IF-2016, Grant Agreement number: 748749, EU. Consejeria de Salud y Familias, Junta de Andalucia, Spain (PI-0318-2018). Instituto de Salud Carlos III, Ministerio de Sanidad, Gobierno de España, Spain (PI17/01004). Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación and Fondo Europeo de Desarrollo Regional, Spain (BFU2017-83588-P to BRG). We thank all the staff of the animal facility at IBIMA (ECAI de Experimentación Animal) and especially its coordinator Dr. Ricardo González Carrascosa for his excellent work. The authors also gratefully acknowledge all the staff of the bioimaging facility at IBIMA (ECAI de Imagen) and the proteomic (ECAI de Proteómica) facility, especially Dra. Carolina Lobo-García for excellent technical assistance. FJBS and IGM belong to the regional "Nicolás Monardes" research program from Consejería de Salud y Familias (C-0070-2012, RC0005-2016, RC-0001-2021 and C1-0018-2019; Junta de Andalucía, Spain). FJBS, NCV and BRG are members of the pancreatic islets study group from the Spanish Society for Diabetes (SED), Spain. CIBERDEM is an initiative of the Instituto de Salud Carlos III, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NR5A2/LRH-1 regulates the PTGS2-PGE2-PTGER1 pathway contributing to pancreatic islet survival and function

  • Martín-Vázquez, Eugenia
  • Cobo-Vuilleumier, Nadia
  • Araujo Legido, Raquel
  • Marín-Cañas, Sandra
  • Nola, Emanuele
  • Dorronsoro, Akaitz
  • López-Bermudo, Lucía
  • Crespo Barreda, Alejandra
  • Romero-Zerbo, Silvana Y.
  • García-Fernández, María
  • Martín-Montalvo, Alejandro
  • Rojas, Anabel
  • Comaills, Valentine
  • Bermúdez-Silva, Francisco Javier
  • Gannon, Marueen
  • Martín, Franz
  • Eizirik, Decio L.
  • Lorenzo, Petra Isabel
  • Gauthier, Benoit R.
LRH-1/NR5A2 is implicated in islet morphogenesis postnatally, and its activation using the agonist BL001 protects islets against apoptosis, reverting hyperglycemia in mouse models of Type 1 Diabetes Mellitus. Islet transcriptome profiling revealed that the expression of PTGS2/COX2 is increased by BL001. Herein, we sought to define the role of LRH-1 in postnatal islet morphogenesis and chart the BL001 mode of action conferring beta cell protection. LRH-1 ablation within developing beta cells impeded beta cell proliferation, correlating with mouse growth retardation, weight loss, and hypoglycemia leading to lethality. LRH-1 deletion in adult beta cells abolished the BL001 antidiabetic action, correlating with beta cell destruction and blunted Ptgs2 induction. Islet PTGS2 inactivation led to reduced PGE levels and loss of BL001 protection against cytokines as evidenced by increased cytochrome c release and cleaved-PARP. The PTGER1 antagonist—ONO-8130—negated BL001-mediated islet survival. Our results define the LRH-1/PTGS2/PGE/PTGER1 signaling axis as a key pathway mediating BL001 survival properties., The authors are supported by grants from the Consejería de Salud, Fundación Pública Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010 to B.R.G., PI-0085-2013 to P.I.L., PI-0247-2016 to F.J.B.S.), the Consejería de Economía, Innovación y Ciencia (P10.CTS.6359 to B.R.G.), the Ministerio de Ciencia e Innovación co-funded by Fondos FEDER (PI10/00871, PI13/00593 and BFU2017-83588-P to B.R.G and PI17/01004 to F.J.B.S.), Vencer el Cancer (B.R.G), DiabetesCero (B.R.G.) and the Juvenile Diabetes Research Foundation Ltd (17-2013-372 and 2-SRA-2019-837-S-B to B.R.G.). E.M.V. is recipient of a Fellowship from the Ministerio de Ciencia e Innovación co-funded by Fondos FEDER (PRE2018-084907). F.J.B.S. is a recipient of a "Nicolás Monardes" research contracts from Consejería de Salud Junta de Andalucía, (C-0070-2012). A.M.M. is supported by CPII19/00023 and PI18/01590 from the Instituto de Salud Carlos III co-funded by Fondos FEDER. V.C. is supported by a AECC investigator award. CIBERDEM is an initiative of the Instituto de Salud Carlos III.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Roles of extracellular vesicles associated non-coding RNAs in Diabetes Mellitus

  • Gauthier, Benoit R.
  • Cobo-Vuilleumier, Nadia
  • López-Noriega, Livia
Extracellular vesicles (EVs), especially exosomes (50 to 150 nm), have been shown to play important roles in a wide range of physiological and pathological processes, including metabolic diseases such as Diabetes Mellitus (DM). In the last decade, several studies have demonstrated how EVs are involved in cell-to-cell communication. EVs are enriched in proteins, mRNAs and non-coding RNAs (miRNAs, long non-coding RNAs and circRNAS, among others) which are transferred to recipient cells and may have a profound impact in either their survival or functionality. Several studies have pointed out the contribution of exosomal miRNAs, such as miR-l42-3p and miR-26, in the development of Type 1 and Type 2 DM (T1DM and T2DM), respectively. In addition, some miRNA families such as miR-let7 and miR-29 found in exosomes have been associated with both types of diabetes, suggesting that they share common etiological features. The knowledge about the role of exosomal long non-coding RNAs in this group of diseases is more immature, but the exosomal lncRNA MALAT1 has been found to be elevated in the plasma of individuals with T2DM, while more than 169 lncRNAs were reported to be differentially expressed between healthy donors and people with T1DM. Here, we review the current knowledge about exosomal non-coding RNAs in DM and discuss their potential as novel biomarkers and possible therapeutic targets., The authors were/are funded by grants from Consejería de Salud, Fundación Pública Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010, December 2010 to BG, PI-0085-2013),; Consejería de Economía, Innovación y Ciencia, Junta de Andalucía (P10-CTS-6359 to BG); Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, cofounded by Fondos FEDER (PI10/00871, January 2011 and PI13/00593, January 2014 to BG); Ministerio de Economía y Competitividad, Plan Nacional(BFU2017-83588-P, January 2018 and PID2021-123083NB-I00, sept 2022 to BG); JuvenileDiabetes Research Foundation JDRF (17-2013-372, August 2013 and 2-SRA-2019-837-S-B, August2019 to BG); Special thanks to ALUSVI (Asociación Lucha y Sonríe por la Vida, Pilas), and the Fundacion DiabetesCERO for their unconditional financial support. LL-N is also funded by Procedimiento de selección de personal investigador Doctor con cargo a las ayudas concedidas mediante la Línea de Ayudas para Captación, Incorporación y Movilidad de Capital Humano de I+D+i (20804).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The PTGS2/COX2-PGE2 signaling cascade in inflammation: Pro or anti? A case study with type 1 diabetes mellitus

  • Martín-Vázquez, Eugenia
  • Cobo-Vuilleumier, Nadia
  • López-Noriega, Livia
  • Lorenzo, Petra Isabel
  • Gauthier, Benoit R.
Prostaglandins are lipid mediators involved in physiological processes, such as constriction or dilation of blood vessels, but also pathophysiological processes, which include inflammation, pain and fever. They are produced by almost all cell types in the organism by activation of Prostaglandin endoperoxide synthases/Cyclooxygenases. The inducible Prostaglandin Endoperoxide Synthase 2/Cyclooxygenase 2 (PTGS2/COX2) plays an important role in pathologies associated with inflammatory signaling. The main product derived from PTGS2/COX2 expression and activation is Prostaglandin E (PGE), which promotes a wide variety of tissue-specific effects, pending environmental inputs. One of the major sources of PGE are infiltrating inflammatory cells - the production of this molecule increases drastically in damaged tissues. Immune infiltration is a hallmark of type 1 diabetes mellitus, a multifactorial disease that leads to autoimmune-mediated pancreatic beta cell destruction. Controversial effects for the PTGS2/COX2-PGE signaling cascade in pancreatic islet cells subjected to diabetogenic conditions have been reported, allocating PGE as both, cause and consequence of inflammation. Herein, we review the main effects of this molecular pathway in a tissue-specific manner, with a special emphasis on beta cell mass protection/destruction and its potential role in the prevention or development of T1DM. We also discuss strategies to target this pathway for future therapies., The authors are supported by grants from the Consejería de Salud, Fundación Pública Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010 to B.R.G., PI-0085-2013 to P.I.L.), the Consejería de Economía, Innovación y Ciencia (P10.CTS.6359 to B.R.G and DOC_00652 to L.L.N.), the Ministerio de Ciencia E Innovación co-funded by Fondos FEDER (PI10/00871, PI13/00593 and BFU2017- 83588-P, PID2021-123083NB-I00 to B.R.G), Vencer el Cancer (B.R.G), DiabetesCero (B.R.G.) and the Juvenile Diabetes Research Foundation (17-2013-372, 2-SRA-2019-837-S-B, 3-SRA-2023-1307-S-B to B.R.G.). E.M.V. is recipient of a Fellowship from the Ministerio de Ciencia E Innovación co-funded by Fondos FEDER (PRE2018-084907).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Enhancing human islet xenotransplant survival and function in diabetic immunocompetent mice through LRH-1/NR5A2 pharmacological activation

  • Cobo-Vuilleumier, Nadia
  • Lorenzo, Petra Isabel
  • Martín-Vázquez, Eugenia
  • López-Noriega, Livia
  • Nano, R.
  • Piemonti, Lorenzo
  • Martín, Franz
  • Gauthier, Benoit R.
The intricate etiology of type 1 diabetes mellitus (T1D), characterized by harmful interactions between the immune system and insulin-producing beta cells, has hindered the development of effective therapies including human islet transplantation, which requires strong immunosuppressants that impair beta cell survival and function. As such alternative immunomodulating therapies are required for successful transplantation. The discovery that pharmacological activation of the nuclear receptor LRH-1/NR5A2 can reverse hyperglycemia in mouse models of T1D by altering, and not suppressing the autoimmune attack, prompted us to investigate whether LRH-1/NR5A2 activation could improve human islet function/survival after xenotransplantation in immunocompetent mice. Human islets were transplanted under the kidney capsule of streptozotocin (STZ)-induced diabetic mice, and treatment with BL001 (LRH-1/NR5A2 agonist) or vehicle was administered one week post-transplant. Our study, encompassing 3 independent experiments with 3 different islet donors, revealed that mice treated for 8 weeks with BL001 exhibited lower blood glucose levels correlating with improved mouse survival rates as compared to vehicle-treated controls. Human C-peptide was detectable in BL001-treated mice at both 4 and 8 weeks indicating functional islet beta cells. Accordingly, in mice treated with BL001 for 8 weeks, the beta cell mass was preserved, while a significant decrease in alpha cells was observed compared to mice treated with BL001 for only 4 weeks. In contrast, vehicle-treated mice exhibited a reduction in insulin-expressing cells at 8 weeks compared to those at 4 weeks. These results suggest that BL001 significantly enhances the survival, engraftment, and functionality of human islets in a STZ-induced diabetic mouse model., The authors are supported by grants from the Consejería de Salud y Consumo, Fundación Pública Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010 and PI-0001-2020 to BRG), the Consejería de Economía, Innovación y Ciencia (P10.CTS.6359 to BRG), the Ministerio de Ciencia E Innovación (BFU2017-83588-P, PID2021-123083NB-I00 financed by MCIN/AEI/10.13039/501100011033 and by FEDER, UE to BRG), The DiabetesCERO Foundation (BRG), the Spanish Diabetes Society and the Juvenile Diabetes Research Foundation (17-2013-372, 2-SRA-2019-837-S-B, 3-SRA-2023-1307-S-B to BRG)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

LRH-1/NR5A2 targets mitochondrial dynamics to reprogram type 1 diabetes macrophages and dendritic cells into an immune tolerance phenotype

  • Cobo-Vuilleumier, Nadia
  • Rodríguez-Fernandez, Silvia
  • López-Noriega, Livia
  • Lorenzo, Petra I.
  • Franco, Jaime M.
  • Lachaud, Christian C.
  • Martín-Vázquez, Eugenia
  • Legido, Raquel Araujo
  • Dorronsoro, Akaitz
  • López-Férnandez-Sobrino, Raul
  • Fernández-Santos, Beatriz
  • Espejo Serrano, Carmen
  • Salas-Lloret, Daniel
  • van Overbeek, Nila
  • Ramos-Rodriguez, Mireia
  • Mateo-Rodríguez, Carmen
  • Hidalgo, Lucia
  • Marin-Canas, Sandra
  • Nano, Rita
  • Arroba, Ana I.
  • Campos Caro, Antonio
  • Vertegaal, Alfred C. O.
  • Martín-Montalvo, Alejandro
  • Martín, Franz
  • Aguilar-Diosdado, Manuel
  • Piemonti, Lorenzo
  • Pasquali, Lorenzo
  • González Prieto, Roman
  • García Sánchez, Maria Isabel
  • Eizirik, Decio L.
  • Martínez-Brocca, Maria Asuncion
  • Vives-Pi, Marta
  • Gauthier, Benoit R.
The complex aetiology of type 1 diabetes (T1D), characterised by a detrimental cross-talk between the immune system and insulin-producing beta cells, has hindered the development of effective disease-modifying therapies. The discovery that the pharmacological activation of LRH-1/NR5A2 can reverse hyperglycaemia in mouse models of T1D by attenuating the autoimmune attack coupled to beta cell survival/regeneration prompted us to investigate whether immune tolerisation could be translated to individuals with T1D by LRH-1/NR5A2 activation and improve islet survival., We thank Dr Maria José Quintero from the Cytometry Core Facility and the team from the Genomic Core Facility of CABIMER, as well as Pedro Antonio Soriano Fernandez and Noelia García Rodríguez for their excellent technical support. Special thanks to all donors and to the Biobank Node of the Hospital Virgen Macarena (Biobanco del Sistema Sanitario Público de Andalucía) which is part of the Spanish National biobanks Network (PT20/00069) supported by Instituto Carlos III and FEDER funds. We acknowledge the support of the Basic Experimentation in Diabetes study group of the Spanish Association of Diabetes as well as positive discussion through the Consolidated Research Group 2021 SGR 00002, AGAUR, Generalitat de Catalunya. We also acknowledge the use of DeepL write and ChatGTP for English editing purposes. The authors are supported by grants from the Consejería de Salud y Consumo, Fundación Pública Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010 and PI-0001-2020 to B. R. G), the Consejería de Economía, Innovación y Ciencia (P10.CTS.6359 to B. R. G and DOC_00652, FSE and Lema: Andalucía moves with Europe to L. L. N.), the Ministerio de Ciencia E Innovación (BFU2017-83588-P, PID2021-123083NB-I00 financed by MCIN/AEI/10.13039/501100011033 and by FEDER, UE to B. R. G.), the DiabetesCERO Foundation (B. R. G.), the Spanish Diabetes Society (B. R. G.) and the Juvenile Diabetes Research Foundation/Breakthrough TD1 (17-2013-372, 2-SRA-2019-837-S-B, 3-SRA-2023-1307-S-B to B. R. G; 3-SRA-2022-1201-S-B(1) to D. L. E.), the National Institutes of Health Human Islet Research Network Consortium on Beta Cell Death & Survival from Pancreatic Beta Cell Gene Networks to Therapy [HIRN-CBDS], (U01 DK127786 to D. L. E.) and the National Institutes of Health, NIDDK (RO1DK126444 and RO1DK133881-01 to D. L. E.). P. A. S. F. is contracted through an action funded by the EU- NextGenerationEU, and the Recovery, Transformation and Resilience Plan (SE/INV/0008/2022) granted to the Consejería de Empleo, Formación y Trabajo Autónomo of the Junta de Andalucía in the 2022 call of the Investigo Program, Mechanism for Recovery and Resilience. E. M. V. is the recipient of a post-doctoral fellowship from the Belgian FNRS., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting LRH-1/NR5A2 to treat type 1 diabetes mellitus

  • Cobo-Vuilleumier, Nadia
  • Lorenzo, Petra I.
  • Gauthier, Benoit R.
Type 1 diabetes mellitus (T1DM) is defined as an autoimmune disease that targets the selective destruction of islet insulin-producing beta cells by infiltrating immune cells (insulitis). As a result, the organism is no longer able to produce insulin and develops hyperglycaemia and, if untreated, death. Despite advances in medical device technology and insulin analogues as well as strives in generating in vitro insulin-producing cells, there is still no robust therapy to substitute and protect beta cells that are lost in T1DM. Clinical trials aimed at blocking the immune-mediated beta cell destruction have had moderate success leaving a gap in our understanding of disease aetiology. Such breach in knowledge may stem from the oversight that inhibiting the immune attack likely impairs beta cell regeneration and emphasizes a fundamental paradigm in the approach to treat the disease: A non-mutually exclusive strategy in which the uncontrolled self-directed inflammatory immune response (and not the global immune system) as well as beta cell regeneration are exquisitely fine tuned in order to successfully regain immunological tolerance and restoration of a functional beta cell mass. As such, defining factors that can guide a pro-inflammatory immune cell destructive environment towards an anti-inflammatory environment facilitating beta cell survival and stimulate regeneration would define an unprecedented class of immune-regenerative therapeutic agents for T1DM. In our recent study we identify the liver receptor homolog 1 (LRH-1, also known as NR5A2) as a 'druggable' target that fulfills these criteria restoring glycemic control in various mouse models of T1DM as well as improving human islet survival and function both in vitro and in vivo (Nat Comms, 9:1488)., The research of B.R.G is/was supported by the Juvenile Diabetes Research Foundation (17-2013-372), the DiabetesCero Foundation, the Consejeria de Salud, Fundacion Publica Andaluza Progreso y Salud, Junta de Andalucia (PI0727-2010), Consejeria de Economia, Innovacion y Ciencia (P10.CTS.6359) and the Ministerio de Economia y Competidividad co-funded by Fondos FEDER (PI10/00871, PI13/00593 and BFU2017-83588-P)., Peer reviewed